Healthcare

Big Pharma’s Drug War: Innovative vs. Generic and Biosimilar Drugs

Big Pharma’s Drug War: Innovative vs. Generic and Biosimilar Drugs By Wayne Schnarr When I started my job in 1989 as a lobbyist for the Canadian generic drug industry, I thought that my job would be accumulating and organizing facts in a logical manner to present to consumer groups, governments ...

Hamilton Thorne is undervalued, says Beacon Securities in coverage launch

Hamilton Thorne (TSXV:HTL) is well-positioned to benefit from the growth in In-Vitro Fertilization (IVF) clinics worldwide, making its stock a cheap pickup, says Beacon Securities analyst Doug Cooper, who has initiated coverage of the company with a “Buy” rating and a $1.40 target price. A manu ...

Bloom Burton & Co. Announces the 2018 Bloom Burton Award Gala

Annual Award Recognizes the Most Significant Contributor to Canada’s Innovative Healthcare Industry  TORONTO, February 12, 2018 – Bloom Burton & Co. (“Bloom Burton”) is thrilled to announce the 2018 Bloom Burton Award Gala, to be held at the Four Seasons Hotel in Toronto, Ontario, Canada ...

Canada in Science – Feb 2, 2018

  Welcome to your Canada in Science Review for February 2nd, 2018! Nat Immunol.  2018 Feb;19(2):192-201. Aged Polymorphonuclear Leukocytes Cause Fibrotic Interstitial Lung Disease in the Absence of Regulation by B cells. Proc Natl Acad Sci USA.  2018 Jan 30. doi: 10.1073/pnas.1716871115. R ...

Plasma for Profit: The Changing Landscape of Blood Donation

Plasma for Profit: The Changing Landscape of Blood Donation By Wayne Schnarr I was going to start writing about the Canadian generic drug industry when I read an article in the Globe and Mail on paid-plasma centres and their potential impact on volunteer Canadian blood supplies. In the summer of 2 ...

Tech Talk for Tuesday January 30th 2018

Pre-opening Comments for Tuesday January 30th U.S. equity index futures are lower this morning. S&P 500 futures were down 11 points in pre-opening trade. Apple dropped $2.00 to $165.96 on reports of a slowdown in iPhone production. The stock is expected to open below support at $166.46. Fourth qua ...

Bulls Stomp On The Gas, Biotechs Explode

Market Recap for Friday, January 26, 2018 The bears were absolutely stymied on Friday as the major indices surged to unprecedented levels.  Despite the very overbought conditions that have persisted on many indices for four months now, bulls dominated the action and show no signs of letting up. ...

HEALTHCARE SPDR HITS NEW RECORD AND IS PLAYING CATCH-UP TO THE REST OF THE MARKET -- AMGEN AND BIOGEN LEAD BIOTECH ISHARES HIGHER

HEALTHCARE SECTOR IS PLAYING CATCH-UP ... Healthcare stocks are off to a good start for the new year, and are one of the market's strongest sectors. That's a big change from the past three years when healthcare was one of the markets weakest laggards. That's another sign that investors are looking ...

Q4 & Annual 2017 Share Price Performance – Part 3

            Tier 2 Canadian Healthcare Companies: A Few Outperformers, Balanced with Usual High Volatility In this blog, I am going to comment on the Q4 and annual 2017 share price performance of the group of 64 companies with share prices of between $0.10 and $0.99 to start 2017 (excludes c ...

Biotech and Finance-Related ETFs Lead as SPY Extends Extraordinary Run

SPY Extends Extraordinary Run. Biotech ETFs Lead Healthcare Sector. Finance-Related ETFs Extend Breakouts. Copper ETN Pulls Back within Trend. Is Telecom Turning the Corner? SPY Extends Extraordinary Run          The major index ETFs remain in strong uptrends, both short-term and long-term. Th ...